Actavis and Adamas Announce FDA Approval of Namzaric(TM), a Fixed-Dose Combination of Memantine Extended-Release and Donepezil Hydrochloride

Indicated for Treatment of Moderate to Severe Alzheimer's Disease DUBLIN and EMERYVILLE, Calif., Dec. 24, 2014 -- (Healthcare Sales & Marketing Network) -- Actavis plc (ACT) and Adamas Pharmaceuticals Inc. (ADMS) today announced that the U.S. Food and ... Biopharmaceuticals, Neurology, FDAActavis , Adamas Pharmaceuticals, Namzaric, Alzheimer
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news